ChemoCentryx, Inc. (CCXI)
CCXI Price and Sentiment
CCXI Latest news
The stock surged after obtaining FDA approval for avacopan.
Amber Specialty Pharmacy Selected by ChemoCentryx to Dispense TAVNEOS™ (avacopan), an Adjunctive Treatment for ANCA-Associated Vasculitis2021-10-13 10:43
OMAHA, Neb.--(BUSINESS WIRE)--Amber Specialty Pharmacy announces that it will begin dispensing TAVNEOS™ (avacopan), a first of its kind orally-administered selective complement 5a receptor inhibitor, as an adjunctive treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis (also known as ANCA-associated vasculitis), in combination with standard therapy. TAVNEOS™ is manufactured by California-based ChemoCentryx, Inc., a biopharma company focus
These two small drugmakers are poised for a long-winded growth spurt.
There's an old saying on Wall Street that "gaps refill." It's true and it may be about to happen to shares of ChemoCentryx, Inc. (NASDAQ:CCXI).
The stock price of ChemoCentryx Inc (NASDAQ: CCXI) increased by over 9% during intraday trading today. This is why it happened.
Appointment Brings More than 20 Years of Drug Development Experience as Company Launches First Product
Investors are excited about the biotech's game-changing new drug.
On Friday, ChemoCentryx Inc. (NASDAQ:CCXI) shares spiked nearly 70% after announcing the Food and Drug Administration (FDA) had approved avacopan for the treatment of ANCA vasculitis. Avacopan is an orally administered small-molecule C5a receptor antagonist, which selectively blocks the effects of C5a through the C5a receptor.
The FDA approves ChemoCentryx's (CCXI) lead drug Tavneos to treat ANCA-associated vasculitis. It is the company's first drug to get FDA approval.